Piper Jaffray analyst, Joshua Schimmer, maintained his Overweight rating on Otonomy (NASDAQ: OTIC) after getting details on the Otiprio launch ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE